Purpose: To measure the Schlemm's canal (SC) in vivo by Fourier-domain optical coherence tomography (FD-OCT) in a Caucasian paediatric population.

Methods: Participants of this cross-sectional study were 290 healthy children. In the right eye of each child, SC cross-sectional diameter and area measurements were made with the FD-OCT instrument RTVue (Optovue Inc, Fremont, CA, USA) in the nasal and temporal quadrants. These SC variables were then assessed for correlation with the factors age, gender, refractive error, anterior chamber angle and trabecular meshwork (TM) metrics. Finally, the reproducibility of the SC measurements was assessed in 30 of the participants.

Results: Mean participant age was 10.7 ± 3.4 years (range 3-18). SC diameters could be measured in both quadrants in 70.6% and 70.4% of subjects, respectively. Mean SC diameters were similar (p = 0.125) for the temporal and nasal quadrants: 266.7 ± 84.1 μm (range 131-509) and 273.2 ± 77.3 μm (range 124-486), respectively. Mean SC areas were also similar (p = 0.167) for the two quadrants: 9975 ± 3514 μm (range 4000-23 000) versus 9688 ± 3297 μm (range 3000-24 000). No differences were detected in SC measurements according to gender, refractive error or angle and TM measurements (R ≤ 0.116; p ≥ 0.125). The exception was age which was directly correlated with SC size (p ≤ 0.041). The reproducibility of the SC measurements was excellent (intraclass correlation coefficients ≥0.936).

Conclusion: FD-OCT allows the identification of the SC in children. Our data indicate an increase in SC size produced with age.

Download full-text PDF

Source
http://dx.doi.org/10.1111/aos.13857DOI Listing

Publication Analysis

Top Keywords

schlemm's canal
8
optical coherence
8
coherence tomography
8
gender refractive
8
refractive error
8
reproducibility measurements
8
measurements
5
range
5
canal measured
4
measured optical
4

Similar Publications

Purpose: To investigate the characteristics and publication status of minimally invasive glaucoma surgery (MIGS) clinical trials registered on ClinicalTrials.gov.

Design: A cross-sectional study.

View Article and Find Full Text PDF

Purpose: Trabecular micro-bypass devices (TBDs) such as the iStent series (Glaukos Corporation, Laguna Hills, CA), are effective in reducing intraocular pressure (IOP). However, precise placement of TBDs is crucial in achieving surgical efficacy, as device malpositioning may lead to suboptimal IOP reduction. We demonstrate two novel intra-operative signs to aid confirmation of accurate iStent placement, without reliance on imaging technologies.

View Article and Find Full Text PDF

Introduction: Cataract surgery has been reported to have a reducing effect on intraocular pressure (IOP) in glaucomatous and non-glaucomatous eyes. This effect seems to be more noticeable in eyes with narrow angles (NAs) than in eyes with open angles (OAs). Decrease in IOP may be a result of the increase in anterior chamber angle (ACA) and Schlemm canal (SC) after cataract surgery.

View Article and Find Full Text PDF

Since the trabecular meshwork (TM) is central to intraocular pressure (IOP) regulation and glaucoma, a deeper understanding of its genomic landscape is needed. We present a multimodal, single-cell resolution analysis of mouse limbal cells (includes TM). In total, we sequenced 9,394 wild-type TM cell transcriptomes.

View Article and Find Full Text PDF

Minimally invasive glaucoma surgeries (MIGS) offer an alternative approach, aiming to be both safe and effective. Defined by their ab interno technique, which avoids creating a bleb, MIGS procedures seek to reduce intraocular pressure (IOP) by enhancing the outflow pathways of aqueous humor. Techniques include stenting, incisions, and excisions of the trabecular meshwork, canaloplasty of Schlemm's canal, and drainage implants that enhance uveoscleral outflow to the subchoroidal space.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!